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Abstract 
The reliability of the foot tapping test (FTT) has not been well identified in a 
normal healthy population. In order to make it clinically relevant, more research must 
be done on the FTT in healthy individuals in order to determine if it is a reliable 
measure of foot tapping ability. Purpose: The purpose of the study was to investigate 
the FTT in a healthy population using a variety of different measurement methods. By 
comparing the different measurement methods, we hope to make recommendations for 
future FTT research.  Methods: 20 healthy individuals (10 male and 10 female), ages of 
18-31, completed a series of foot tapping trials spread out over 4 separate visits. While 
seated, subjects tapped their foot repeatedly for 10 seconds while researchers counted 
the number of foot taps. The starting foot was randomized during each visit and each 
foot would be tested twice with the shoes ON and twice with the shoes OFF (resulting 
in 8 trials per visit * 4 visits = 32 trials per subject). The number of foot taps was 
determined with visual inspection, video playback (slowed and normal speed), and with 
the use of a force plate. The mean values of the FTT trials were compared across days, 
dominant vs. non-dominant foot, the shoes ON/OFF conditions, and with the different 
counting methods.  Results: Significant differences were found in foot tapping rates in 
the shoes ON vs shoes OFF and dominant vs. non-dominant foot analyses (p<0.05). 
Furthermore it was found that a significant difference in the mean number of foot taps 
existed between visit 1 and the other 3 visits (p>0.05).   It was found that the FTT 
exhibited high test-retest reliability (Pearson r >0.80) and high Cronbach’s alpha (alpha 
>0.80) across the live, slowed video counts, and force plate measurements for both the 
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shoes ON and shoes OFF trials. Results allowed authors to make further suggestions for 














































 Though seemingly simple enough, tapping the foot repeatedly in quick 
succession actually requires a precise and rapid modulation of both motor unit 
recruitment and discharge rates [1]. Often taken for granted, the ability to properly 
plantar and dorsi flex the foot at the ankle joint is an important component to human 
locomotion. Of particular concern is the act of dorsiflexion, or the raising of the toes 
during gait. It is the job of the anterior tibialis muscle to dorsiflex the foot during gait in 
order to prevent oneself from tripping over their toes. [2-4]. Poor control or weakness of 
the anterior tibialis during gait can result in a phenomenon known as foot drop in which 
the foot is unable to be lifted high enough off the ground to clear the swing phase of gait 
resulting in a dragging of the toes [2-4]. Consequently foot drop negatively impacts 
walking efficiency and may increase the likelihood of falling, which increases fall 
related injuries [3, 4].  
There can be many different causes of foot drop but the most common instances 
appear to be associated with a lower motor neuron dysfunction such as in cases of 
damage to the L4-L5 vertebrae or peripheral neuropathy. [5] Of particular concern to 
our lab though is the presence of foot drop associated with upper motor neuron 
dysfunction, which is a common symptom in individuals with Multiple Sclerosis [4, 6]. 
In cases of suspected upper motor neuron dysfunction, foot drop could be associated 
with nerve compression between the cortex and lumbar nerves, axonal or demyelination 
damage, or central lesions. [5]  
Analogous to the presence of foot drop is a slowing of rapid and repetitive 
movements in patients with motor neuron disorders. In cases where a motor neuron 
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dysfunction may be suspected it is not uncommon for physicians or researchers to 
conduct neurological assessments. One such test is known as the Foot Tapping Test or 
FTT. The foot tapping test is an assessment that requires the subject to rapidly and 
repetitively contract the lower limb for 10 seconds [1, 7-11]. The test is performed in a 
seated position with legs bent at 90° and heel firmly planted on the ground, the FTT 
requires the subject to tap the ball of their foot against the ground as many times as 
possible for 10 seconds [1, 7-11]. The number of times the subject is able to tap their 
foot is then counted and compared to that of a healthy control [1, 7, 9, 11]. Much like in 
raising the toes during walking, the anterior tibialis muscle is primarily responsible for 
dorsiflexing the foot during the FTT [1, 7]. It is hypothesized that a person’s ability to 
rapidly and repetitively tap the foot is indicative of the proper functioning of the upper 
motor neurons responsible for dorsiflexion of the foot. [1, 7, 9, 12] Therefore if 
someone experiences a FTT score significantly lower than that of a healthy control 
subject then it could be indicative of a dysfunction of the upper motor neurons. 
It has been shown in past research that there is a significant reduction in foot 
tapping speed in certain clinical populations such as the elderly [7] and those affected 
by Cervical Myelopathy [9], Amyotrophic Lateral Sclerosis [1, 8], Parkinson’s 
disease[13] or multiple sclerosis[10, 11]. In these clinical populations it was found that 
the maximum number of foot taps performed during the FTT were significantly reduced 
compared to a healthy control population [1, 7, 9, 11, 13]. In such populations it is 
hypothesized that the reduction seen in foot tapping speed could be associated with a 
loss or damage to motor neurons responsible for the contraction of the lower limbs [1, 
7-9, 12, 14]. To that end, the FTT is an ideal method for assessing one’s ability to 
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produce a rapid repetitive movement. Not only is the FTT, simple, and cheap but the 
FTT is appropriate for a wide range of different clinical populations including those 
who are non-ambulatory or have difficulties maintaining their balance[9].  
Despite the allure of the FTT as a means of discerning motor neuron dysfunction 
there are still many problems that prevents it from being used to it’s full potential. One 
such problem is the lack of a normative FTT score for healthy individuals [9]. Without 
normative foot tapping data from healthy individuals, it makes it difficult for physicians 
and researchers to discern what is or isn’t normal for a person of a given age or clinical 
status. To date, studies of the FTT have only been concerned with showing some mean 
difference in foot tap scores between a diseased population and control group[1, 7, 9, 
11, 13]. No study to date has been specifically designed to identify normative values or 
even standard guidelines for testing procedures for the FTT in an exclusively healthy 
population. What data does exist on normative FTT scores tends to vary depending on 
the methodology used (range of means: 31-47 taps in healthy individuals) [1, 7, 9]. 
Without better agreement on normative values and testing procedures the FTT will 
remain limited in it’s ability to use the FFT as a means for screening for motor neuron 
dysfunction.  
Even more concerning, are the inconsistency in methodologies seen between 
FTT studies [1, 7-13, 15]. During a MEDLINE search a variety of inconsistencies 
regarding testing procedures were seen ranging from test duration, counting method, 
and even subject positioning [1, 7-13, 15]. These inconsistencies make it difficult to 
determine the standard error of the measure associated with the FTT and calls into 
question it’s very reliability and validity. If all of the studies utilizing the FTT had used 
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a standardized protocol then we could at least estimate a normal range of foot taps using 
their data from healthy control subjects.  
 Testing an individual’s ability to perform rapid repetitive movements is a crucial 
aspect of any neurological exam because often times a decline in voluntary contraction 
rate can be one of the earliest signs of a central disorder of motor control[14]. Up to this 
point, very little research has been done on the foot tapping test in a normal healthy 
population. Researchers and physicians have shown sufficient evidence to suggest that 
there is indeed a difference in the maximum number of foot taps performed during the 
FTT in certain clinical populations as compared to a healthy control [1, 7, 9, 11]. 
However, because of a lack of consistency in foot tapping test procedures between 
studies, it makes it hard to generalize their findings in a way that would make it useful 
for physicians trying to assess a patient’s level of motor function.  
PURPOSE 
 Therefore, the primary purpose of this study was to investigate the reliability of 
the foot tapping test in a normal healthy population. By studying the FTT in a healthy 
population, it is our hopes to elucidate not only the reliability of this test but to establish 
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Research Questions 
1. What is the reliability of foot tapping test and the various methods of counting 
it? 
2. What is the number of trials/visits to determine stability? 
Sub-Questions 
1. Is there a significant difference in the maximum number of foot taps when performing 
the FTT with or without shoes on? 
2. Is there a significant difference between the number of foot taps counted when counting 
with live, video playback, or force plate methods?  
Research Hypotheses 
1. Ho ; We hypothesize that the proposed FTT protocol will exhibit a high level of 
reliability. 
2. Ho ; We hypothesize that there will be a significant learning effect between trials or 
visits.. 
Sub-Hypotheses 
1. Ho ; We hypothesize that there will be no significant difference in the number of foot 
taps performed with either shoes on or off. 
2. Ho ; We hypothesize that there will be significant differences in the number of foot taps 
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Significance of the Study: 
 The foot tapping test happens to be one of the easiest and fastest methods to 
assess the presence of upper motor neuron dysfunction [14]. The test is quick, simple, 
non-invasive, and appropriate for even non-ambulatory individuals[9]. In previous 
research it has demonstrated that the number of foot taps in certain clinical populations 
is significantly less than that of healthy controls. Despite everything that’s been learned 
from the FTT thus far, many problems still exist due to the inconsistency of the FTT in 
past studies. By studying the foot-tapping test in healthy populations, we hope to 
expand the current knowledge base as well as elucidate the reliability of the FTT using 
a variety of different counting methods. This study serves not only as an investigation 
into the reliability of the FTT in healthy population, but also serves as a guide for future 
researchers. By being as thorough and descriptive as possible in describing our FTT 
methodology, it is our hopes that this study will aid in developing a sound standardized 
procedure for conducting FTT research in the future. 
Delimitations 
The delimitations of this study include: 
1. Healthy individuals between the ages of 18-31. 
2. Individuals with no known disease or injury affecting the lower limbs. 
3. Women who are pregnant are not permitted to participate in this study. 
Limitations 
1. Participants were recruited on a volunteer basis; therefore, they may not 
represent all healthy individuals ages 18-31 years old. 
2. Physical activity outside of the study was not controlled for. .  
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Assumptions: 
1. Participants provided accurate information with regards to known injuries or 
diseases affecting lower limbs. 
2. Participants gave max effort with each test. 
3. Participants adhered to pretesting guidelines 
Operational Definitions: 
1. Foot tapping Test (FTT): A test in which the subject must rapidly tap the foot 
against the ground from a seated position as many times as possible within 10 
seconds. The number of foot taps has been correlated with upper motor neuron 
function [1, 7, 9, 12, 13].  
2. Upper Motor Neurons (UMN): Motor neurons that originate in either the 
motor cortex or in the brain stem. The loss of UMNs has been shown to 
negatively affect central motor drive [1, 8, 9, 12].  
3. Central Motor Drive (CMD): Amount of efferent motor nerve output to 
skeletal muscle [16, 17]. 
4. Amyotrophic lateral sclerosis (ALS): A chronic degenerative disease that 
destroys nerve cells in the brain and spinal cord leading to the loss of upper and 
lower motor neurons. Can lead to loss of voluntary muscle control, slowing of 
contraction speed, muscle weakness and wasting, and hyporeflexia [1, 8, 18]. 
5. Parkinson’s Disease (PD): A chronic and progressive movement disorder 
resulting from the destruction of the dopamine producing brain cells of the 
substantia nigra. Characteristics of Parkinson’s disease include the slowing of 
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voluntary movements, tremors at rest, rigidity, and postural instability [13, 19, 
20]. 
6. Multiple Sclerosis (MS): A chronic and progressive autoimmune disease that 
affects the central nervous system leading to damage of the myelin sheath of the 
motor axons. Symptoms can vary but fatigue, delayed reaction and cognitive 
ability, motor weakness, impaired coordination, bladder dysfunction, and 
sensory disturbances are all common complaints [10, 16, 21, 22]. 
7. Validity: The degree to which a test actually measures what it is intended to 
measure [23]. 
8. Reliability: Describes the degree to which a test will provide consistent results 
when repeated [23]. 
9. Test-retest Reliability: A measure of the reliability when a test is completed 
multiple times over a period of time [23] 
10. Inter-rater Reliability: A measure of reliability used to express the degree to 
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CHAPTER II 
REVIEW OF LITERATURE 
INTRODUCTION 
 The foot tapping test (FTT) is an exam that can be used to assess motor neuron 
and central drive dysfunction in a variety of different clinical populations [1, 7-10, 12, 
13]. It has been hypothesized that damage to the upper motor neurons is associated with 
changes in central motor drive that lead to a slowing of contraction speed, slowed 
repetitive movements, weakness, and decreased muscle activation which can all 
translate into a higher fall risk [1, 19, 24]. To that end it is believed that the maximum 
number of foot taps a person is able to perform in 10 second period is reflective of 
proper functioning of the upper motor neurons (UMN) responsible for contraction of the 
lower limbs [1, 7, 9, 10, 12].  
Previous research has shown a correlation between the maximum number of 
foot taps and various measures of UMN dysfunction [1, 9, 13, 25]. The FTT is an ideal 
method for testing UMN function because it is quick, non invasive, doesn’t require any 
special equipment and is even appropriate for non-ambulatory individuals [9]. The FTT 
has been previously utilized in studies involving clinical populations such as those with 
amyotrophic lateral sclerosis [1, 8], Parkinson’s disease [13], multiple sclerosis [10], 
and cervical myelopathy [9]. In these populations the mean number of toe taps was 
found to be significantly less than those of a healthy control sample.  
Despite showing a decreased rate of foot tapping in clinical populations as 
compared to healthy populations, , we still don’t know much about the FTT in a healthy 
population. [1, 7, 9, 10] Currently, no study to date has examined the FTT in an 
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exclusively healthy population. Because no study to date has examined the FTT in a 
healthy population it makes it hard to say what exactly is and isn’t a normal range of 
foot taps for a healthy individual without a UMN. Therefore without normative values 
across ages it is difficult to make clinical judgments of UNM function without this 
critical information.  
In addition to a lack of normative foot tapping values, is the lack of a 
standardization of testing procedures. Depending on the research group, the FTT can 
differ in the test duration, anywhere from 10-15 seconds or untimed altogether, to the 
positioning of the subject from lying down in supine position to sitting with legs at 90°, 
the method of counting foot taps from visual inspection to using a specially made 
counting device, and other aspects related to methodology (i.e. number of testers, leg 
order, unilateral/bilateral testing, rest intervals, etc.) [1, 7-13, 15]. The fact that the FTT 
methodology tends to differ so much between studies is a cause for concern because it 
brings into question the reliability and validity of the FTT as means of assessing central 
drive and motor neuron dysfunction. A more standardized protocol would surely serve 
to make the FTT a more valid and reliable test of motor function. Not to mention testing 
procedures should adhere to consistent standards to provide the most robust and 
generalizable data possible. 
 This review of literature will be used to examine the utilization and 
methodology of the foot tapping test in previous research. By examining the previously 
used methodologies it is our hopes to identify the shortcomings of the FTT in previous 
research in order to design a more sound protocol. The remainder of the chapter will be 
broken into the following sections: FTT in Clinical Populations, FTT in Healthy 
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Populations, Subject Placement, Foot tap Counting Methods, FTT Reliability, and Foot 
Tapping Rate and Age.  
FTT In Clinical Populations  
In patients with Amyotrophic Lateral Sclerosis (ALS) there has been evidence to 
suggest that rapid repetitive foot movements are slowed compared to controls [1]. In a 
study by Kent-Braun et al 1998, foot tapping speed was measured in 27 patients with 
ALS and in 15 healthy age/gender matched controls. It was found that the mean number 
of foot taps in ALS patients was 23.9 ± 2.4 steps/10s and was significantly less than that 
of the healthy control subjects whom averaged 43.2 ± 1.5 steps/10s. In a six-month 
follow-up, 13 of the original 27 ALS patients were brought back in order to remeasure 
foot tapping speed. It was found that the max number of foot taps in these 13 ALS 
patients was reduced from 25 ± 4 taps to 18 ± 5 taps over a 6-month period. The authors 
of the study attributed the decline in foot tapping speed to a further progression of 
disease and a significant change in UMN function during this period [1]. 
Similarly, in a study by Mitsumoto et al 2007, researchers also found a 
significant decline in foot tapping speed over time in ALS patients. In this study, 30 
patients with ALS were tested for foot tapping speed (mean visits: 3) over an average of 
9.2 months (range: 6-15 months). It was found that the patients with ALS saw a mean 
decline in foot tapping speed of about 1.90 ± .65 steps per month. Additionally it was 
found that foot tapping ability is correlated to central motor conduction time to hand/leg 
muscles (r=0.33, p=0.01) and NAA/tCr ratio(r and p not given) [8]. 
In a study by Gunzler et al 2009, the number of foot taps was measured in 50 
patients with Parkinson’s disease. It was found that for repetitive foot tapping, the mean 
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number of taps was 32.2 taps/15 seconds [13]. There was no healthy control population 
to compare the results to but the number of foot taps would suggest an impairment of 
UMN function when you consider results found by other FTT studies. A few things to 
consider when comparing foot taps in this study to other similar studies is the time of 
the test and how foot taps were recorded. For this study the foot tapping test was 
extended to 15 seconds instead of the usual 10 seconds. Also, researchers decided to use 
a custom made foot tapping device that required the subject to exert at least 2.72 kg of 
force in order to depress the pedal that counted the steps. The fact that these researchers 
used a longer testing time and a custom made device probably makes the results less 
comparable to other studies utilizing the FTT. These differences will be later discussed 
in the Foot Tapping Counting Methods section. 
 In a study by Numasawa et al, the FTT was evaluated in 252 patients with 
cervical myelopathy and 792 healthy individuals. It was found that the subjects with 
cervical myelopathy had a significantly reduced number of foot taps (23.8 ± 7.2 
steps/10s) compared to the healthy subjects (31.7 ± 6.4 steps/10s) [9]. In the 
myelopathic group it was found that the FTT score significantly correlated with the 
lower extremity motor function of modified Japanese Orthopedic Association score 
(r=0.662, P<0.0001). Additionally this study tracked 126 of the myelopathic 
participants who underwent surgery to relieve their symptoms of cervical myelopathy. It 
was found that the average value of the FTT improved from 22.4 ± 7 steps/10s to 28.4 ± 
8.1 at 1 year postoperatively and continued to strongly correlate with JOA scores 
(r=0.431, P<0.0001). 
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 Again, despite showing a decrease in foot taps in these clinical populations as 
compared to a healthy control, the FTT is still limited by the fact that we still don’t 
really know what is considered a “normal” range of foot taps. Because we don’t really 
know what a normal range of foot taps is for a healthy individual is it makes the FTT 
less reliable as a means for detecting the presences of a UMN dysfunction. Right now 
there’s no minimum threshold number of foot taps for determining what is and isn’t 
considered a possible sign of UMN dysfunction.  
FTT in Healthy Populations 
 So far very little research has been done on the FTT in healthy populations. 
Many studies that have looked at the FTT in diseased populations have also looked at 
the number of foot taps in a healthy control population [1, 7, 9, 10]. However to date, no 
study has had its primary objective as to examine the reliability of the FTT in an 
exclusively healthy population. The mean number of foot taps in healthy populations 
tends to vary from study to study and this likely is due to variations in testing methods 
and study design. In order to determine what is considered a “normal” range of foot taps 
for the FTT more studies must be conducted using a healthy population across an age 
range. It is necessary to see if the differences in the mean number of foot taps found in 
healthy controls between studies are due to varying procedures or some other 
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Subject Placement 
 An important part of any examination is the proper placement of the subject. 
Depending on what kind of examination is being conducted the improper placement of 
a subject could yield drastically different results. Unfortunately, up to this point there 
hasn’t really been any comparative studies on the FTT that has sought to determine the 
most efficient and reliable method of collecting foot tap data [1, 7-10, 12, 13, 15]. 
Because the action of dorsiflexion is most often used while walking you would think 
that the most logical method for a FTT would be to have the subject stand up while 
tapping. However when you start testing clinical populations such as the elderly, those 
with MS, ALS, CM, or Parkinson’s disease, balance, pain, spasticity, and fatigue start to 
become an  issue to test while standing, therefore the most logical modification to 
standing is to have the participant in a seated position [1].  
Probably the most common way you see the FTT being performed is the method 
described in a study of ALS patients by Kent-Braun et al 1998 [1]. In this study, both 
ALS and healthy control subjects performed the FTT in order to see if there was a 
significant reduction in foot tapping speed of the ALS group.  The FTT was performed 
from a seated position with the knees and hips at 90 degrees of flexion. With the heel 
firmly planted the subjects were then instructed to tap the floor with the ball of their 
foot as quickly as possible for 10 seconds. It is unclear exactly why the researchers 
chose to use a testing interval of 10 seconds for the FTT. This method would later be 
used in other studies that utilized the FTT likely because it was fast and didn’t require 
any special equipment [1, 7-10]. A further description of the study’s sample groups and 
findings will be discussed later in this review. 
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 In another study by Miller and Johnston 2005, subjects were required to perform 
a foot tapping test while lying down in the supine position while tapping their foot 
against a physician’s hand[12]. This study will be further discussed in the FTT counting 
methods section. 
Foot Tap Counting Methods 
During the FTT, the number of foot taps is most often visually inspected at the 
time of testing [1, 7, 9]. This is probably advantageous for many studies because it is 
fast and doesn’t require any expensive equipment. However the downside to this 
method is that it relies on the researcher’s often-subjective observations, which can 
increase the likelihood of human error. To remedy this some studies have used a custom 
built device to measure the number of foot taps rather than relying on visual inspection 
[13, 15]. For studies with especially large sample sizes using a piece of equipment to 
count the number of foot taps is advantageous from not only a time perspective but also 
because it doesn’t require multiple researchers in order to count foot taps.  
In a study by Gunzler et al.2009, the rate of foot tapping was measured in 
patients with Parkinson’s disease with a custom built device that required the subjects to 
depress a lever with their foot [13]. This device consisted of two pedals separated by 30 
cm. Each pedal required the subject to exert at least 2.72 kg of force in order to push it 
36mm to it’s bottom limit. The sensor output would range from 0 to 982 Ω and would 
require the pedal to be depressed by at least 20% before the computer program would 
count the movement as a foot tap [13]. Researchers failed to mention this in their paper 
but it is assumed that the pedal was spring loaded so that the pedal would return to the 
start position after each foot tap. The fact that the pedal produced resistance and was 
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possibly spring loaded is problematic to the study because we cant really be sure how 
much the number of foot taps could be related to some kind of fatigue effect as a result 
of having to depress the pedal repeatedly. It follows that if the pedal was spring-loaded 
it may have also made the dorsiflexion movement a passive movement rather than the 
subject needing to actively dorsiflex the foot. It is unclear if such a device would be 
appropriate for a foot tapping test as we cant really be sure how the resistance from the 
plantar flexion movement and the assumed spring loaded aid during the dorsiflexion 
movement may be affecting the results. Unfortunately the researchers in this study did 
not compare their device to the more commonly used FTT method described by Kent-
Braun et al 1998 [1].  
In another study by Knights and Moule 1967, foot tapping was measured in 
children with the use of a finger counter mounted on the end of a 6x10-in board. The 
tapping lever was installed perpendicularly 1
3/4
 inches above the board and at 30 
degrees from the horizontal. The lever itself was spring loaded and had to be depressed 
¼ inch with at least 400 gm of force in order to be counted [15].  Like in the study by 
Gunzler et al [13] we cant really be sure if the resistance produced by the pedal affected 
the total number of foot taps . Again, the researchers did not compare their method of 
foot tap counting to a more common protocol such as that by Kent Braun et al [1]. 
Some studies utilizing the FTT either didn’t count the number of foot taps or 
failed to mention in their methods section exactly how foot tap data was collected [7, 8, 
10]. In a study by Miller and Johnston[12], foot tapping ability was measured by 
assessing the speed of the foot taps rather than the actual number able to be performed. 
In this study foot tapping speed was assessed in ten subjects by ten different physicians. 
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Eight of these ten subjects suffered from some kind of known upper motor neuron 
dysfunction.  By blinding the physicians from the subject’s medical history this study 
sought to determine whether foot tapping rate or the Babinski test better predicted the 
presence of UMN dysfunction.  
The Babinski sign is a well-known sign of upper motor neuron dysfunction and 
is widely considered an essential element of any complete neurological exam [12]. A 
physician assesses the presence of the Babinski sign by stroking the sole of a patient’s 
foot and examining the subsequent reflex. In a healthy individual the normal response 
during the Babinski sign test is the flexing of the big toe. However in a person 
presenting signs of a neurological disorder the big toe has been seen to extend and may 
be accompanied by the fanning of the toes [26]. As such each physician would take a 
turn in examining the ten subjects. The patients were asked to lie down on their back in 
the supine position and were each tested for the Babinski reflex and asked to perform a 
foot tapping test by rapidly tapping their foot against the physician’s hand.  However 
rather than actually counting the number of foot taps, the physicians were asked to 
assess the rate of foot tapping as either slow or normal[12]. The obvious problem with 
this method is that the rate of foot tapping couldn’t be objectively measured and instead 
relied upon the physicians’ subjective opinion on what’s considered slow or normal. It 
was found that the agreement with known motor neuron weakness was found to be 56% 
for the Babinski sign and 85% for foot tapping [12]. This seems to indicate that foot 
tapping rate could possibly be a more sensitive measure of UMN dysfunction. 
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FTT Reliability 
Because there’s so many different ways the FTT has been conducted between 
studies it is unclear as to what kind of reliability to expect in a normal healthy 
population. A study by Gunzler et al 2009 examined the FTT in individuals with 
Parkinson’s disease and found that at least three practice tests should be performed 
when using the foot tapping test [13]. There appears to be about a 14% increase in the 
number of foot taps between the first of three trials and the scored trial (4
th
 trial) of the 




 trial to the learning 
effect.  
In a study by Numasawa et al 2012, researchers sough to quantify the number of 
foot taps in patients with cervical myelopathy (CM) and healthy individuals [9].It was 
found that the FTT scores tends to have high test-retest reliability for both legs in the 
healthy control (Left: r=0.899, Right: r=0.931)  and cervical myelopathy (Left: r=0.899, 
Right: r=0.934) subjects. Furthermore it was found that the mean number of foot taps 
did not significantly differ from left to right side for both groups (means not reported) 
[9]. 
Though the actual number of foot taps was not counted, the previously 
mentioned study by Miller et al 2005 is one of the only studies that examined the 
interobserver reliability of foot tapping speed. Over the course of 199 independent tests 
it was found that the evaluation of the rate (rated as either slow or normal) of foot 
tapping was substantially high (kappa= 0.73) for the ten different researchers. The 
interrater reliability for the Babinksi sign (another measure of UMN function) was 
found to be significantly less (kappa= 0.30).  
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Unfortunately most studies either don’t report interrater reliability or don’t 
assess it all. It is unclear if other FTT studies utilize one or multiple observers when 
counting foot taps and how they would reconcile the numbers if there were multiple 
counters. 
Foot Tapping Rate and Age 
It has been show from past FTT data that age negatively correlates with foot 
tapping speed.[7, 9]. In a study by Kent-Braun and Ng 1999, foot tapping speed was 
measured in 24 young (32 ± 1 year) and 24 older (72 ± 1 year) individuals.  It was 
found that the maximum number of foot taps in otherwise healthy elderly individuals 
(34 ± 1 tap) was significantly less than that of young individuals (47 ± 1 tap) [7]. The 
researchers concluded that the slowing of foot tapping speed seen in the older group is 
likely due to an age related decline in the ability to rapidly modulate discharge rates and 
motor unit recruitment [7].   
A similar decline in the ability to rapidly tap the foot was also seen in the FTT 
study by Numasawa et al [9]. In this study, foot tapping speed was assessed in 792 
healthy individuals (mean age: 57.5 years) and 252 individuals with cervical 
myelopathy (mean age: 64.8 years). It was found that foot tap speed tends have a 
moderate negative correlation with age in both the healthy control (R= -0..369, 
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SUMMARY  
As previously discussed a person who suffering from some kind of UMN 
dysfunction would likely exhibit an impaired ability to perform rapid and repetitive 
movements [1, 7-10, 13, 14]. By testing a person’s maximum number of foot taps a 
physician could then compare it to a known values in healthy populations to detect and 
track the progression of dysfunction. There has been very little research done to 
examine the reliability of a standardized foot tapping test in healthy populations. In 
order to better detect UMN progression through use of the FTT, a standardized and 
reliable protocol must be established and more research must be done in order to 





















 Up to this point very little research has been done on the foot tapping test in an 
exclusively healthy populations. When you look at data on the FTT in healthy controls, 
the average number of foot taps tends to vary from study to study depending upon the 
methods used. [1, 7, 9, 13] Because there is such poor agreement between studies on the 
average foot tapping score for healthy individuals it dilutes the efficacy of the FTT as a 
means for testing for UMN function. Furthermore   very little data even supports the 
hypothesis that the FTT is reliable in healthy subjects. Therefore the purpose of this 
study is to determine the associated error and reliability of the FTT in a healthy 
population. From this we may hopefully then be able to elucidate a normal expected 
range of foot taps for a healthy individual unaffected by any motor neuron dysfunctions.  
 This chapter contains the methodology for the current study. This includes a 
description of the samples, research design, data collection procedures, instrumentation, 
and data analyses. 
SAMPLE 
 For this study, 20 healthy subjects ages 18-31 were assessed. Subjects were 
recruited thru word of mouth, email and fliers from the Oklahoma City and Norman 
areas. In order to participate in the study, subjects were required to sign an informed 
consent form, which was approved by the University of Oklahoma Institutional Review 
Board (Health Sciences Center). In order to be considered for the study participants 
must be free from any known diseases or injuries that affect the lower limbs.  
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RESEARCH DESIGN 
This study utilized a repeated measures design with one group of healthy 
individuals. Testing took place over four visits and was not allowed to exceed a period 
of four to five weeks from the start date. At least 24 hours was required between visits 
in order to prevent any possibility of fatigue. Visit 1 consisted of the filling out of 
paperwork, subject measurements, protocol familiarizing, and 8 recorded trials of the 
FTT. Visits 2-4 consisted of the same 8 recorded trials. See Table 1 below. 
Visit 1: 
On the first visit, subjects were given a briefing of the study and allowed to ask 
any questions they may have had. If they wished to continue they were given an 
informed consent, HIPPA form, and several other questionnaires.  After completing the 
paperwork the subject’s age, sex, height, weight, and shoe size were recorded. They 
were then familiarized with the foot tapping protocol and allowed to practice each of the 
different protocols. Once comfortable with the procedures, the subject’s positioning was 
notated to ensure proper placement in future trials. Foot placement was notated by 
measuring the position of the big toe relative to a grid painted on the force plate (ex: C3, 
B2, etc). Subjects then performed the first set of 8 trials, 4 with shoes on and 4 with 
shoes off. For both the shoes on and shoes off conditions, 2 trials were performed for 
each leg. Randomization was used in order to determine the starting order of either the 
left or right leg for each visit. Trials were recorded using two tripod-mounted cameras. 
Foot tapping was simultaneously counted during trials by visually counting and with the 
use of the force plate.  
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Visits 2-4: 
For Visits 2-4 the FTT protocol remained exactly the same as in the 1
st
 vist. 
Similarly the starting leg (i.e. left or right) was randomized for each visit.  
 
Table 1: Example Visit Protocol Outline: 
 Daily Procedures Est. Time 
Visit 1 1. Informed Consent 
2. Familiarization 
3. Subject measurement 
4. 4 FTT trials shoes on 
5. 4 FTT trials shoes off 
60 mins 
Visits 2 & 3 1. 4 FTT trials shoes on 
2. FTT trials shoes off 
30 mins 
Visit 4 1. 4 FTT trials shoes on 





Foot tapping test (FTT) 
 For the foot tapping test all subjects were seated in a chair with their knees bent 
at a 90-degree angle. Subjects were asked to sit up straight with their back supported by 
the chair. The feet should be parallel with each other and far enough forward so that 
balls of the feet come to rest on the force plate. If the subject is too short to sit with their 
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back against the chair and still touch the floor with their feet, then they were asked to sit 
as far forward.as necessary to make contact with the force plate. Subjects were 
instructed that their feet should be positioned on the outer edge of the force plate in such 
a way so that the balls of the feet were resting on the plate while the heel of their foot 
was completely off of the force plate. Subjects were asked to dorsi and plantar flex the 
foot while keeping the heel in contact with the floor. If the subject was positioned 
correctly then there should be no force applied to the plate during dorsi flexion. The 
position of the subject’s big toe was noted and used as a reference for repositioning the 
subject in later trials. 
The procedure was then explained and the subject was allowed to practice the 
various protocols. Once comfortable with the procedures and given a chance to rest, the 
subjects started the recorded FTT trials. The starting leg (left or right) was determined 
at random for each visit. 4 trials (2 left and 2 right) were performed with shoes on, 
followed by 4 trials with shoes off. The subjects were given a countdown and started 
tapping on “Go”. While keeping the heel of the foot in contact with the floor the 
subjects tapped the sole of their feet against the floor as many times as possible in 10 
seconds. At the end of the 10 seconds, the subject was instructed to stop and the visual 
and force plate counts were saved. 
Shoes ON vs. shoes OFF  
As the protocol implies there were 4 trials of the FTT with shoes off at the end 
of each visit. This was done with the hope of determining if it made a significant 
difference in the number of taps counted. For these trials the subjects simply took off 
their shoes and set them aside. The type of shoes worn for testing was not standardized 
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beyond instructing the participant to wear what they would normally wear for 
recreational activity. We asked that the participant continue to use the same pair of 
shoes throughout the remaining visits.  
Count Method 
 In order to measure the FTT, foot tapping rates were counted 6 different times 
for each trial, producing 6 measurements per trial. Each trial was counted visually (live 
count) and with the use of a force plate during the actual trial. They were then again 
reviewed by two different counters (counter 1 and counter 2) at a normal and slowed 
speed via video playback (producing 4 different video counts).  
FTT with force plate  
 Force plate data was collected using the NeuLog Force Plate Logger (Model 
NUL-225, NeuLog, Rochester, NY) and NeuLog data acquisition software 7.46.31. 
During each FTT trial, the force plate was used to measure the number of foot taps 
being performed. This was done by having the subject’s positioned on the force plate in 
such a way so that when they tapped their foot, the plate was able to pick up the force 
produced by tap. This information was then graphically displayed allowing each tap to 
be visually counted as a spike in the graph. 
DATA MANAGEMENT 
 All data was collected using the NEULOG data acquisition software. It was then 
exported to a password protected excel spreadsheet and saved on the hardrive of a lab 
laptop. Video files were immediately transferred to the laptop hardrive and the files 
deleted from the camera. The laptop remained locked away in a file cabinet in the Body 
Composition and Physical Performance Lab when not in use. 
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STATISTICAL ANALYSES 
 Results were reported as means ± standard deviation (SD). Statistical tests were 
ran with SPSS version 22 for windows. In order to determine if there was a significant 
difference in foot taps between trials 1 and 2 of each condition, a paired sample T-tests 
were ran. In order to determine if there was a significant difference between foot taps 
between dominant and non-dominant feet, paired samples t-tests were performed. In 
order to determine if day-to-day differences in foot tapping existed, a repeated measures 
ANOVA was ran for each condition. To determine if there was a difference in foot 
tapping between shoes on vs. shoes off conditions, a paired samples T-Test was 
performed. To determine if there was a significant difference in foot taps between the 
various counting methods a repeated measures ANOVA was used. To estimate the 
reliability of the FTT, the cronbach’s alpha was calculated between 4 methods of 
interest. The Pearson R correlation was also calculated between trials 1 and 2 of each 
condition as a measure of test-restest reliability. Effect sizes were calculated and 
reported as Cohen’s D (small, d= .2, medium, d= .5, large, d= .8). Significance for all 
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CHAPTER IV 
RESULTS AND DISCUSSION 
 The present study was conducted to evaluate the foot tapping test in a group of 
healthy individuals. The primary purpose this study was to determine the reliability of 
the foot tapping test. To that end, the FTT was examined and compared under various 
counting and testing conditions. Doing so will allow our researchers to make future 
recommendations as to the most reliable methods of conducting the FTT. The results 
obtained will be presented here in the following sections: Subject Characteristics, Trial 
1 vs. Trial 2, Dominant vs. Non-Dominant, Day-to-Day differences, Shoes ON vs Shoes 
OFF, Slowed vs. Unslowed, Inter method Count Comparison, and Reliability 
Coefficients. 
SUBJECT CHARACTERISTICS 
 20 healthy individuals (10 male and 10 female) between the ages of 18-31 were 
recruited for this study. All subjects were reportedly healthy and were free from any 
known injuries or diseases that may affect the lower limbs. The subject characteristics 
are displayed in Table 2. 
Table 2: Subject Characteristics 
Variables Males (n=10) Females (n=10) 
Age (years) 25.10 (3.18) 22.70 (3.20) 
Height (cm) 178.95 (8.60) 166.63 (7.62) 
Weight (kg) 81.80 (11.25) 74.33 (18.90) 
Shoe Size (cm) 27.95 (1.15) 24.85 (1.30) 
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TRIAL 1 VS TRIAL 2 
 In order to determine the appropriateness of collapsing the data across trials 1 
and 2 for each condition, a series of paired samples t-tests were performed. No 
significant difference between trials 1 & 2 for any of the counting conditions was 
observed (all p<.05). Table 3 displays the means, mean difference, p-value, and 
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Table 3: Mean Differences in Foot Tapping Between Trials 1 and 2 
   
Counting Condition Trial 1 Trial 2 Mean Dif. p-value Cohen's d 
Live 51.51 (10.27) 51.39 (9.75) 0.11 (4.66) 0.664 0.01 
Counter 1 (normal) 51.42 (10.05) 51.11 (9.36) 0.31 (4.16) 0.190 0.03 
Counter 1 (slow) 52.77 (10.05) 52.28 (9.98) 0.49 (4.50) 0.053 0.05 
Counter 2 (normal) 55.76 (13.54) 55.49 (12.97) 0.27 (5.09) 0.354 0.02 
Counter 2 (slow) 56.95 (13.42) 56.45 (13.21) 0.50 (5.47) 0.105 0.04 
Force Plate 45.33 (8.58) 45.10 (8.43) 0.23 (3.65) 0.268 0.03 
Group mean (SD) 
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Figure 1: Mean Difference in Foot Tapping Between Trials 1 and 2  
 
 Mean (SE) 
DOMINANT VS NON-DOMINANT 
 In order to determine whether the dominant, non-dominant, or the mean of both 
feet should be used in comparing foot taps, another series of paired samples t-tests was 
performed. It was found that the dominant foot exhibited a significantly higher rate of 
foot tapping than the non-dominant foot under all counting conditions (p>.05). Table 4 
displays the means, mean differences, p values, and Cohen’s d for the dominant and 
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Table 4: Mean Differences in Foot Tapping Between Dominant and Non-Dominant 
Feet 
  
Counting Condition Dominant Non-Dominant Mean Dif. p-value Cohen's d 
Live 52.39 (9.55) 50.50 (9.76) 1.89 (4.60) 0.00 0.20 
Counter 1 (normal) 51.86 (9.28) 50.64 (9.58) 1.22 (3.36) 0.00 0.13 
Counter 1 (slow) 53.53 (9.87) 51.62 (9.91) 1.92 (5.35) 0.00 0.19 
Counter 2 (normal) 56.87 (12.76) 54.50 (12.91) 2.37 (6.28) 0.00 0.19 
Counter 2 (slow) 58.05 (12.71) 55.61 (13.28) 2.44 (6.10) 0.00 0.19 
Force Plate 46.53 (8.11) 43.94 (8.25) 2.59 (4.83) 0.00 0.32 
Group mean (SD) 
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Figure 2: Difference in Foot Tapping Between Dominant and Non-Dominant Feet 
 
Group Mean (SE). *Significant mean difference existed between dominant and non-dominant at p≥.05. 
DAY-TO-DAY DIFFERENCES 
 Now, using just foot tapping measures from just the dominant foot, the day to 
day foot tapping rates were compared for each of the counting conditions. In order to 
determine if foot tapping results were stable from day-to-day, a repeated measures 
ANOVA was ran on all of the counting conditions across the 4 visits. The ANOVA 
results indicated that only Day 1 tended to differ significantly from the other 3 days for 
all 6 counting conditions. In general, day 1 values were the lowest values. All other 
days (2 thru 4) were not significantly different from each other. Results are displayed in 
Table 5 and Figure 3.  Table 5 indicates when there was a significant difference 
between day 1 and other days as the mean difference and p value used to determine 
significance. An “x” denotes that there was no significant difference between that day 
and day 1 for that particular counting condition. So for example, for the Live count, 
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Day 1 Counting Condition 2 3 4 
Live  -3.31, 0.04 x x 
Counter 1 (normal) X x x 
Counter 1(slow) -3.35, 0.00 -3.51, 0.00 -3.912, 0.02 
Counter 2 (normal) x -3.58, 0.03 X 
Counter 2 (slow) x -3.89, 0.01 -4.66, 0.01 
Force Plate -2.18, 0.04 x X 
Group mean differences and p score 
 x= Non significance 
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SHOES ON VS. SHOES OFF 
 In order to determine how the shoes ON and shoes OFF values should be 
handled, a series of paired samples t-tests were ran for each of the counting conditions. 
Having shown a significant difference in the 1
st
 day trials and dominant feet, analyses 
were ran with all first day and non-dominant trials removed. Results indicated that there 
was a significant reduction in foot tapping when performed with shoes OFF under the 
live, counter 1 (normal), and force plate counting methods. Table 6 contains the group 
means, mean differences, p values, and Cohen’s d for the shoes ON vs. shoes OFF 
conditions. Figure 4 displays these mean differences graphically.  
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Table 6: Mean Differences Between Shoes ON and Shoes OFF Trials 
  Counting Method Shoes ON Shoes OFF Mean Diff. p-value Cohen's d 
Live 54.02 (9.30) 51.40 (8.90) 2.62 (3.88) 0.00 0.29 
Counter 1 (normal) 52.80 (9.28) 51.53 (8.53) 1.28 (4.45) 0.03 0.14 
Counter 1 (slow) 54.57 (9.87) 54.29 (9.31) 0.28 (4.23) 0.62 0.03 
Counter 2 (normal) 58.05 (11.69) 57.58 (12.92) 0.47 (5.52) 0.52 0.04 
Counter 2 (slow) 58.78 (11.83) 59.29 (12.31) 0.51 (5.39) 0.47 -0.04 
Force Plate 47.77 (7.97) 46.19 (7.35) 1.58 (4.53) 0.01 0.21 
Group means (SD) 
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Figure 4: Mean Difference Between Shoes ON and Shoes OFF Trials 
 
Mean (SE). *Significant mean difference existed between shoes ON and shoes OFF trials at p≥.05 
 
 
SLOWED VS NORMAL VIDEO COUNTS 
 In order to determine if there was a significant difference between the slowed 
and unslowed video counts, for the both the shoes on and shoes off trials, a series of 
paired t-tests was ran. Again, statistical analyses were run omitting the visit 1 and non-
dominant foot trials. It was found that significantly more foot taps were counted when 
using the slowed video playback method of counting as compared to normal speed 
counting in all cases except for counter 2’s shoes ON counts. Results for each of the 
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Table 7: Mean Differences in Foot taps Between Normal and 
Slowed Video Counts 
   Counter (shoes/no shoes) Normal Slowed Mean Diff. p-value Cohen's d 
Counter 1(shoes) 52.80 (9.28) 54.57 (9.87) -1.76 (4.79) 0.01 -0.19 
Counter 1 (no shoes) 51.53 (8.53) 54.29 (9.31) -2.76 (5.40) 0.00 -0.31 
Counter 2 (shoes) 58.05 (11.69) 58.78 (11.82) -0.73 (4.40) 0.20 -0.03 
Counter 2 (no shoes) 57.58 (12.92) 59.29 (12.31) -1.71 (3.82) 0.00 -0.07 
Group mean (SD) 
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Figure 5: Mean Differences in Foot Taps Between Normal and Slowed Video 
Counts  
 
Means (SE). *Significant mean difference existed between normal and slowed video counts at p≥.05 
 
INTER METHOD COUNT COMPARISON 
To compare the mean number of foot taps measured with each counting method, 
repeated measures ANOVA was calculated for both the shoes on and shoes off trials. 
Day 1 and non-dominant foot trials were again omitted from analyses. 
SHOES ON: 
 For the shoes ON trials, the repeated measures ANOVA revealed a significant 
difference between all counts (p<.05) except between the live count and counter 1’s 
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Table 8: Inter method Count Comparison (shoes ON) 
Counting Condition Count 
Live 54.02 (9.30) 
Counter 1 (slow) 54.57 (9.87) 
Counter 2 (slow) 58.78 (11.83) 
Force Plate 47.77 (7.97) 
Values expressed as group means (SD) 
 
Figure 6: Inter method Count Comparison (shoes ON) 
 
Group Mean (SE). * Significant mean difference between all counting conditions 
 
SHOES OFF: 
 For the shoes OFF trials, the repeated measures ANOVA revealed a significant 
difference between all counting methods (p<.05). 
Table 9: Inter method Comparison (shoes OFF) 
Counting Condition Count 
Live 51.40 (8.90) 
Counter 1 (slow) 54.29 (9.31) 
Counter 2 (slow) 59.29 (12.31) 
Force Plate 46.19 (7.35) 
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Figure 7: Inter method Count Comparison (shoes OFF) 
 





To determine the reliability of the 4 measures of interest, the Cronbach’s alpha 
was calculated for both the shoes on and shoes off trials. As always, the 1
st
 day and non-
dominant trials have been removed from analyses. Between the 4 main methods of 
interest, the Cronbach’s alpha was high for both the shoes ON and shoes OFF trials 
(cronbach’s alpha of .907 and .867 respectively). The cronbach’s alpha after each item 
was deleted from the comparison are displayed for the shoes ON and shoes OFF trials 
in tables 10 and 11. For both the shoes ON and shoes OFF conditions, the cronbach’s 
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Table 10: Shoes ON Inter method cronbach's alpha. 




Cronbach's alpha after 
removal 
Live 54.02 (9.3) .893 
Count 1 (slow) 54.57 (9.87) .851 
Count 2 (slow) 58.78 (11.83) .913 
Force Plate 47.77 (7.97) .865 
Values reported as group means (SD) 
  
Table 11: Shoes OFF Inter method cronbach's alpha. 




Cronbach's alpha after 
removal 
Live 51.4 (8.9) .837 
Count 1 (slow) 54.29 (9.31 .784 
Count 2 (slow) 59.29 (12.31) .890 
Force Plate 46.19 (7.35) .815 
Values reported as group means (SD) 
  
TEST RETEST RELIABILITY 
 To test the immediate test-restest reliability of the FTT when using the 4 
methods, the Pearson’s R correlation was calculated between trials 1 and 2. These 
correlations may be found in table 12. 
Table 12: Trials 1 and 2 Pearson R 
Correlations 
Count Condition Correlation 
 Shoes Live .876 
 Shoes Count 1 (slow) .893 
 Shoes Count 2 (slow) .910 
 Shoes Force Plate .880 
 NS Live Count 1 (slow) .906 
 NS Count 1 (slow) .939 
 NS Count 2 (slow) .922 
 NS Force Plate .887 
 Correlations between trials 1 and 2 
P value= 0.00 for all correlations 
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DISCUSSION 
 To our knowledge, this is the first study attempting to measure the foot tapping 
test simultaneously using 6 different methods over 4 different visits while also looking 
at the differences with shoes ON and OFF. Past studies have largely neglected to report 
reliability measures or even their methodology used to obtain said values. We were 
particularly interested in the aspects not mentioned in studies (i.e. shoes ON or OFF, 
dominant vs. non-dominant feet, number of trials, etc.) and how they may affect mean 
foot tapping values and the test’s reliability. Without understanding the reliability of the 
FTT itself, it makes it impossible to trust our results and apply them meaningfully. So to 
that end, the current study was designed in a way so that we may get a better idea of the 
reliability of the FTT under various conditions and how it affects mean foot tapping 
rates. The results of the current study will be further discussed here in the coming 
sections. 
TRIAL 1 VS. TRIAL 2 
 For each condition of the foot tapping test (i.e. left foot with shoes ON or right 
foot with shoes OFF), 2 trials were performed. This produced quite a lot of data when 
you consider that each testing condition had two trials and over 4 visits this resulted in 
32 foot tapping scores for each subject. In order to reduce the amount of data we were 
working with, that meant that we either had to remove one of the trials, or average them 
together. To determine if there was a significant difference in foot tapping counts 
between trials 1 and 2, a series of paired sample t-tests were ran. It was found that there 
was no statistically significant difference between trials 1 and 2 as counted by the 
different methods. Table 3 reports these findings as the group means, mean difference, 
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and mean difference p-score. Figure 1 depicts the mean differences graphically as well. 
It is also worth noting that the effect size was very small (Cohen’s d <.05) between 
trials 1 and 2 for all counting conditions. From this, it was determined that it would be 
appropriate to average the two trials together in order to collapse the data. For the 
remainder of the discussion, when referring to a FTT trial, we are actually referring to 
the mean score of trials 1 and 2. 
DOMINANT VS. NON-DOMINANT 
 In order to determine whether the dominant, non-dominant, or the mean of the 
two should be used when comparing foot tapping scores, another series of paired 
sample t-tests was used. Dominant vs. non-dominant foot tapping scores for each 
counting method were compared and it was found that the dominant foot had a higher 
rate of tapping as rated by each of the counting conditions (see Table 4). Figure 2 
depicts the dominant vs. non-dominant mean difference score for each foot tapping 
which were all considered significant. Despite showing a statistically significant 
difference, the Cohen’s d calculations revealed a small effects size (Cohen’s d <0.2) 
between dominant and non-dominant trials for all counting conditions except the force 
plate which was slightly higher at d=0.32.  As this was a healthy group of individuals 
and no asymmetries were to be expected, it was decided that the dominant foot would 
be used for all comparisons from here on out. In a study that seeks to quantify 
asymmetry scores or is studying clinical populations it may be more appropriate to keep 
and analyze both legs or simply use the mean difference scores for the two legs. 
Another foot tapping study by Numasawa et al found no significant difference between 
legs, which is contrary to the findings of the current study [9]. 
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DAY-TO-DAY DIFFERENCES 
 In order to determine if there was any significant difference in foot tapping rates 
between days, a repeated measures ANOVA was ran for the different counting 
conditions. Results of the ANOVA (Table 5) indicated that the only day that varies 
significantly for any of the counting conditions was the 1
st
 day. The mean foot tapping 
scores on the 1
st
 day tended to be significantly less than that of the other days. The only 
counting condition that did not seem to significantly change from the 1
st
 day was 
counter 1’s normal speed playback counts. These relationships are displayed graphically 
in Figure 3. The tendency for that first day to be significantly lower than the other three 
days led researchers to decide that that first day should be thrown out from future 
analyses.  
This change from the 1
st
 day to the rest was attributed to the learning effect. 
Similarly, in a study by Gunzler et al, a learning effect was found to occur in the FTT. 




 trial of the FTT that a 14% increase 
occurred. It was therefore their recommendation that at least 3 practice trials be given 
[13]. It was for this reason, that when designing the current study, the subjects were 
given many opportunities to practice during the familiarization. Even though a 
familiarization period was utilized before testing on the first day, it did not appear 
sufficient to account for the learning effect seen. It is therefore our recommendation that 
a more extensive familiarization be done on a separate day before the actual day of 
testing. Perhaps by giving subjects a day or so between the familiarization and the first 
day of testing (rather than the same day) may lesson the learning effect across trials. 
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SHOES ON VS. SHOES OFF 
 One particular thing of interest to the researchers in this study was the effect of a 
person’s shoes on their ability to perform the foot tapping test. It reasons that the weight 
or shape of a person’s shoe may affect their foot tapping speed. Individual differences 
in shoe size and shape may make the comparison of foot tapping rates between subjects 
less reliable and thus performing the test with the shoes off may alleviate said issue. In 
order to determine if there was a significant difference in foot tapping ability when 
having shoes ON vs shoes OFF, a series of paired sample t-tests were performed. 
Results of the paired sample t-tests indicated that while the shoes ON trials tended to be 
higher than the shoes OFF trials, the shoes ON trials were only statistically significant 
for the Live, counter 1 (normal), and force plate counting conditions. Even then, despite 
the three counting conditions showing a sig. difference, the effect size remains small for 
shoes ON vs shoes OFF (Cohen’s d≤0.20). These results can be found in Table 6 and 
graphically on Figure 4.  
 Few if any foot tapping studies have indicated how the test was performed in 
regards to the shoes. For the current study, the type of shoe worn was not controlled for 
other than ensuring that the shoe remained the same throughout the 4 visits. Because it 
couldn’t be definitively said which measure was better (shoes ON or OFF), it was 
decided by researchers to keep both the shoes ON and shoes OFF trials separate in all 
future analyses in order to better understand how shoes may affect foot tapping 
measures. To truly understand the effects of shoes on foot tapping rates another study 
must be done that seeks to better classify shoe type by style, material, size, and heel 
thickness.  
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SLOWED VS. NORMAL SPEED PLAYBACK 
 The task of reviewing foot tapping can be quite tedious so researchers were 
interested in seeing if their was any real difference between counting foot tapping with 
either the normal speed or slowed speed video playback. In order to determine if there 
was a significant difference in the mean foot taps counted with the slowed and normal 
speed video playback methods, a series of paired sample t-tests was ran for both the 
shoes ON and shoes OFF conditions. It was found that the slowed video count was 
significantly higher for counter 1 for both the shoes ON and OFF conditions. In counter 
2 however, there was only a significant increase in the mean foot taps for the shoes OFF 
condition. Table 7 and figure 5 displays these values.  
 It was decided by researchers to go ahead and remove the normal speed counts 
from the final analyses due to the fact that there was a statistically significant difference 
in 3 out of the 4 cases and also the fact that it logically seems to make sense that a 
slowed down video may be used to more accurately assess foot tapping. 
 INTERMETHOD COUNT COMPARISON 
 In order to determine if there was a significant difference in the number of foot 
taps counted with the varying counting methods, a repeated measures ANOVA was ran 
for both the shoes ON and shoes OFF testing conditions.  
SHOES ON 
 For the shoes ON trials, it was found that the mean foot tapping score was 
significantly different for all 4 of the methods of interest (p values >.05) except for the 
comparison between the live count and counter 1’s slow count. Table 8 and Figure 2 
display the mean counts and SD for each method.  
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SHOES OFF 
 For the shoes OFF trials, it was found that the mean foot tapping score was 
significantly different for all 4 methods of interest (p values >.05). The means and SD 
for each method are displayed in Table 9 and Figure 3. 
 For both the shoes ON and shoes OFF trials it was found that the force plate 
count tended to be the lowest mean of all 4 counts but also tended to have the least 
standard deviations. Interestingly for the shoes ON trials there was found to be no 
significant difference between the live count and slowed count 1 but there was a 
significant difference for the shoes OFF trials. For both the shoes ON and shoes OFF 
trials, counter 2’s counts tended to be significantly higher than counter 1’s but also 
tended to have a higher standard deviation. 
RELIABILITY COEFFICIENTS 
 In order to determine the reliability of the 4 measures of interest, the Cronbach’s 
alpha for the 4 measures, as well as their individual Pearson correlations were 
calculated.  
CRONBACH’S ALPHA 
 The cronbachs alpha for the 4 methods was calculated separately for the shoes 
ON and shoes OFF trials. It was found that both the shoes ON and shoes OFF trials 
exhibited a high Cronbach’s alpha for the 4 methods (alpha: .907 and .867 respectively). 
For both the shoes ON and shoes OFF trials it was found that the cronbach’s alpha 
would increase with the exclusion of Counter 2’s trials. See tables 10 and 11 for mean 
and cronbach’s alpha values.  
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PEARSON’S R CORRELATIONS 
 In order to determine the immediate test-retest reliability of the 4 different 
methods, the Pearson’s R correlation was calculated between trials 1 and 2 of each of 
the 4 counts of interest for the shoes ON and shoes OFF trials. It was found that all 4 
methods had a high level of correlation (R>.80) between trials 1 and 2 for the shoes ON 
and shoes OFF trials. 
 Because all of the values were so close it becomes difficult to definitively say 
which is better. The Cronbach’s alpha analysis revealed that the statistic would actually 
increase with the exclusion of counter 2’s values. One possible explanation of this is the 
fact that counter 2 may not have been as personally invested in counting as counter 1 
who was one of the primary investigators in this study. 
 Having discussed all the aspects of the FTT examined in the current study, it 
becomes apparent that still more research must be done to examine the FTT. Even 
though a significant difference was shown with the dominant/non-dominant and shoes 
ON/shoes OFF comparisons, effect sizes were still shown to be small (Cohen’s d <0.20) 
in these cases. It raises still the question of whether these effects are strong enough to be 
worth controlling. Evidence of the current study would seem to suggest that some kind 
of learning effect seems to take place between trials and visits and that familiarization 
may be more important than once. Once corrected for however (1
st
 day and non-
dominant trials removed), the FTT was shown to have a high reliability (Pearson’s R 
>0.80 and Cronbach’s alpha >0.80) for the live count, slowed video, and force plate 
trials. These aspects and their clinical implications will be further discussed in the 
conclusion section. 
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CHAPTER V 
CONCLUSION 
 The purpose of this study was to investigate the reliability of the foot 
tapping test in a normal healthy population. By investigating reliability measures of the 
FTT in a healthy population it was our hopes to identify it’s shortcomings as well as 
make recommendations as to the best method of counting in future FTT research.  
RESEARCH QUESTIONS 
1. What is the reliability of foot tapping test and the various methods of counting 
it? It was found that the foot-tapping test had a high test-retest reliability (R>.80) 
for all measurement methods. It was also found that the 4 main methods of 
interest had a high cronbach’s alpha (>.80) for both the shoes on and shoes off 
trials though they may benefit by the removal of 2
nd
 counter. 
2. What is the number of trials/visits to determine stability? It was determined that 
when conducting the FTT, that it is necessary to conduct a more extensive 
familiarization period. Even with our familiarization on the first visit, there was 
still a significant difference in the mean foot tapping scores on the 1
st
 day 
compared to others. A separate familiarization day rather than simply before the 
first recorded trial may help to alleviate this issue. 
SUB QUESTIONS 
1. Is there a significant difference in the maximum number of foot taps when performing 
the FTT with or without shoes on? Yes, it was found that there was a significant 
difference between the FTT mean score with shoes ON vs shoes OFF. The FTT with 
shoes on was found to generally be higher but it could not be definitively said which 
was the most appropriate for measuring foot tapping ability. It reasons that the shoes 
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OFF trials may be more comparable between subjects because it removes any 
possibility of shoe effects.  
2. Is there a significant difference between the number of foot taps counted when counting 
with live, slowed video playback (with two separate counters), or force plate methods? 
Yes, it was found that all 4 counts differed significantly from each other. The live 
counts tended to be closer to counter 1’s than they were to counter 2’s. Both counters 
tended to count more foot taps with slowed video playback than the initial live count. 
The force plate had a tendency to produce the lowest foot tapping score but also showed 
the least variability (mean SD).  
CLINICAL SIGNIFICANCE 
 There are a few things that can be taken away from this study in terms of clinical 
significance. The first and foremost of which is in regards to the inter day differences. It 
was found that the first day was significantly less than other days for some of the 
counting methods. Even though a familiarization period was utilized on visit 1, the 
mean trials of visit 1 were still considered significantly lower than that of other visits 
which suggests that there was some kind of learning effect taking place. It is unclear 
whether this learning effect occurred between the trials of visit 1 (i.e. between trial 
1,2,3,4,5,6,7, or 8) or whether it occurred at some point between days (i.e. between 
visits 1 & 2). The clinical implications of these findings seem to imply that the FTT 
might not be an appropriate test to perform and measure on a one-time basis. By this, 
we mean that it may not be appropriate to introduce someone to the FTT and get 
recorded measures within the same visit. It reasons that if a learning effect is indeed 
present between visits, then those values seen on visit 1 may not reflect a true measure 
of a person’s foot tapping ability. So instead, it may be more useful for a clinician or 
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researcher to conduct the FTT over multiple visits to get an idea of a person’s foot 
tapping ability. Another caveat of conducting the FTT across multiple visits is that it 
could potentially be used as a measure of a treatment effect or disease progression. That 
being said however, the measuring of the FTT over multiple visits may has it’s own 
inherent problems. It raises the question of whether the learning effect seen with the 
FTT remains consistent over time, or is it necessary to refamiliarize a person every 
single visit or every other few visits. Furthermore, if we see significant changes in foot 
tapping rates between visits, how can we be certain whether this is the effect of a 
treatment/disease or simply the influence of the learning effect. 
It was also found that though small, there was a statistically significant 
difference found between the trials with shoes ON and trials with shoes OFF.  The 
shoes ON trials tended to be higher than those of their shoes OFF counterparts, which  
may suggest that the type of shoes has an effect on a person’s ability to rapidly tap their 
feet. So the question now is; should we conduct the FTT with the shoes ON or OFF? It 
reasons that a person’s foot tapping with shoes ON would more closely correlate with 
ADL where shoes are typically worn (i.e. walking, climbing stairs, working, etc.).  
However on the other end, it reasons that having the shoes ON also invites a lot more 
room for variability and error. For example, if it were to turn out that the type of shoe 
(meaning: shape, size, heal thickness, weight, etc) effected foot tapping rate then it 
would necessitate controlling for the type of shoes worn by subjects. That means not 
only would ALL the subjects have to wear a similar type of shoe but they would also 
have to consistently wear the same pair of shoes throughout testing. One way of 
remedying this problem is to have all subjects perform the FTT with shoes OFF. 
   52 
Though taking the shoes OFF may relieve the problem of shoe type it raises some of it’s 
own issues. As previously mentioned, the FTT with shoes ON may more closely 
correlate to ADL requiring the shoes to be ON.  Furthermore it may not always be 
practical to remove the shoes of those who are non-ambulatory, have balance deficits, 
or have difficulty removing and putting on their shoes.  
In terms of reliability, we’ve shown that the FTT is a reliable measure of foot 
tapping ability (Pearson’s R and Cronbach’s alphas >.80) with both the shoes ON and 
OFF across the live, Counter 1 and 2’s slowed video counts and force plate measures. 
Despite this, all 4 measurements were found to be significantly different from each 
other (with the exception of the Live vs. Counter 1 (shoes ON trials). The cronbach’s 
alpha actually suggested that counter 2’s removal might benefit the reliability of the 4 
measures of interest. In this study, the inclusion of the 2
nd
 rater only served to increase 
variability in the FTT measures. Though the FTT may appear to show strong reliability 
within the same rater, it’s reliability between different raters remains questionable. To 
that end, it would be advisable that the raters remain consistent throughout the live and 
video recorded counts. 
Despite showing less foot taps with live counting compared to the video 
playback method, it is advisable to still utilize a live count when conducting the FTT. 
Not only does technology have a way of failing at the most inopportune of times, but 
also in many clinical settings, it just wouldn’t be practical to record and review 
hundreds of patient’s foot tapping videos.  The use of the force plate data also shows 
potential clinical relevance as it allows for researchers to quickly get a measure of foot 
tapping rates without the need for live counting or video playback methods. The use of 
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a force plate would be beneficial in a clinical setting as it offers an objective measure of 
foot tapping rate, which means that it would no longer necessitate the same tester for 
every single FTT trial.  At a bare minimum, all clinical foot tapping data should utilize a 
live count and either a slowed video or force plate count. Ideally the inclusion of a force 
plate is desirable as it allows for an objective measure. It is however understandable that 
some clinics not wish to purchase extra equipment. 
FUTURE RESEARCH 
 Despite this study being a good starting point, more research needs to be done 
on the foot tapping test in healthy individuals and eventually clinical populations. 
Specifically more research needs to be done on the effects of shoes on foot tapping 
measurements. Furthermore the use of a force plate or similar counting device should be 
further studied as it potentially offers a more convenient and precise measurement of 
foot tapping ability. It may also be useful to see if a person’s daily activity levels as well 
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 Consent Form 
University of Oklahoma Health Sciences Center (OUHSC)  
University of Oklahoma Norman Campus 
An Evaluation of the Foot Tapping Test (FTT) in a Healthy Population  
Principal Investigator: Rebecca D. Larson, PhD 
 
This is a research study. Research studies involve only individuals who choose to 
participate. Please take your time to make your decision. Discuss this with your family 
and friends. 
 
Why Have I Been Asked To Participate In This Study? 
You are being asked to take part in this trial/study because you are a healthy individual 
who is free from any known diseases or injuries that may affect the lower limbs.  
 
Why Is This Study Being Done? 
The primary purpose of this study is to determine the validity and reliability of the foot 
tapping test in a normal healthy population free of known diseases or injuries affecting 
the lower limbs. A secondary goal of this study is to elucidate a normal expected range of 
foot taps for an individual of this population. 
 
How Many People Will Take Part In The Study? 
About 100 people will take part in this study and all participants will participate at the 
Body Composition and Physical Performance Lab at the University of Oklahoma.  
 
What Is Involved In The Study? 
If you take part in this study, you will have the following tests and procedures: 
 
Visit 1: 
For the first visit we will discuss the purpose of the study and the details of each of the 
study visits. If you so choose to participate you will be asked to read and sign this form. 
You will also fill out a health status questionnaire and physical activity questionnaire. 
 
After completing the questionnaires your height, weight, and shoe size will be measured. 
You will then be familiarized with the foot tapping test using the force plate with your 
shoes both on and off. You will be seated in a chair and required to rapidly and 
repeatedly tap your foot against the ground in 10-second intervals several times. You will 
be allowed to practice the test several times until you feel comfortable performing it with 
shoes on and off. You will then be asked to perform the first set of recorded trials. The 
number of times that you are able to repeatedly tap your foot in 10 seconds will be 
assessed using a force plate, with visual inspection of the researchers, and will be video 
recorded for later analysis. This will be done twice for each leg under the two conditions 
(shoes on and shoes off) for a total of 8 trials. You will be allowed two minutes of rest 
between each trial. 
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Visit 1 will take approximately 60 minutes. 
 
Visits 2-4: 
For visits 2-4, the exact same FTT protocols as visit 1 will be followed in order to 
measure foot tapping speed. Testing order, number of trials, and conditions will remain 
the same throughout all visits. At the end of the 4
th
 visit you will undergo a full body dual 
X-ray absorptiometry (DXA) scan in order to measure the amount of lean body mass in 
your lower limbs. This procedure will require you to lie down and remain still for about 
10 minutes. 
 
Visits 2 and 3 should take approximately 30 minutes 
Visit 4 will take approximately 60 minutes 
 
 
How Long Will I Be In The Study? 
We think that you will be in the study for a total of 2-3 weeks where you will visit the 
Body Composition and Physical Performance Lab on 4 occasions. Each visit will take 
approximately 30 minutes to 1 hour to complete 
 
There may be anticipated circumstances under which your participation may be 
terminated by the investigator without regard to your consent. 
 If it is determined that it is in your medical best interest. 
 Your condition worsens. 
 New information becomes available. 
 You fail to follow study requirements. 
You can stop participating in this study at any time. However, if you decide to stop 
participating in the study, we encourage you to talk to the researcher and your regular 
doctor first.  
 
What Are The Risks of The Study?  
Risks and side effects related to this study include: 
 
DXA 
During the DXA scan, you will be exposed to a very low dose of radiation. 
 
This study involves exposure to radiation from an x-ray procedure that is being 
performed for research purposes only, and not required for medical care. The amount of 
radiation exposure is equivalent to less than the daily amount of natural background 
radiation exposure people in the United States receive. The risk of radiation is cumulative 
over your lifetime. 
 
The radiation exposure in this study may be hazardous to an unborn child. As such you 
will be asked to perform a simple urine test to determine possible pregnancy. The test 
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will be free. A negative pregnancy test is needed prior to participating in the DXA scan. 
For unexpected pregnancies, subjects are encouraged to speak with their family 
physician. 
 
The DXA and other research procedures are not for diagnostic purposes and if you have 
any questions about your test results, you should see a physician. 
 
Are There Benefits to Taking Part in The Study?  
There is no direct medical benefit in participating in this study. 
 
What Other Options Are There?  
You may chose to not participate in the study. 
 
What about Confidentiality? 
Efforts will be made to keep your personal information confidential. You will not be 
identifiable by name or description in any reports or publications about this study. We 
cannot guarantee absolute confidentiality. Your personal information may be disclosed if 
required by law.  You will be asked to sign a separate authorization form for use or 
sharing of your protected health information. 
 
There are organizations outside the OUHSC that may inspect and/or copy your research 
records for quality assurance and data analysis. These organizations include the US Food 
& Drug Administration and other regulatory agencies, the OUHSC Human Research 
Participant Program office, the OUHSC Institutional Review Board, and the OUHSC 




What Are the Costs? 
There is no cost to you if you participate in this study. 
 
Will I Be Paid For Participating in This Study? 
There will be no monetary compensation for participating in this study. 
 
What if I am Injured or Become Ill While Participating in this Study? 
Taking part in this study is voluntary. You may choose not to participate. Refusal to 
participate will involve no penalty or loss of benefits to which you are otherwise entitled. 
If you agree to participate and then decide against it, you can withdraw for any reason 
and leave the study at any time. You may discontinue your participation at any time 
without penalty or loss of benefits, to which you are otherwise entitled. 
 
What Are My Rights As a Participant? 
Taking part in this study is voluntary.  You may choose not to participate.  Refusal to 
participate will involve no penalty or loss of benefits to which you are otherwise entitled. 
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If you agree to participate and then decide against it, you can withdraw for any reason 
and leave the study at any time.  You may discontinue your participation at any time 
without penalty or loss of benefits to which you are otherwise entitled. 
 
We will provide you with any significant new findings developed during the course of the 
research that may affect your health, welfare, or willingness to continue your 
participation in this study.  
 
You have the right to access the medical information that has been collected about you as 
a part of this research study.  However, you may not have access to this medical 
information until the entire research study has completely finished. You consent to this 
temporary restriction. 
 
Whom Do I Call If I have Questions or Problems? 
 
If you have questions, concerns, or complaints about the study or have a research-related 
injury, contact Dr. Rebecca Larson at 352-359-8432 (cell) or 405-325-6325 (office). 
 
If you cannot reach the Investigator or wish to speak to someone other than the 
investigator, contact the OUHSC Director, Office of Human Research Participant 
Protection, at 405-271-2045. 
For questions about your rights as a research participant, contact the OUHSC Director, 






By signing this form, you are agreeing to participate in this research study under the 
conditions described. You have not given up any of your legal rights or released any 
individual or entity from liability for negligence. You have been given an opportunity to 
ask questions. You will be given a copy of this consent document. 
 
I agree to participate in this study: 
 
_________________________________  _______________________  _________ 
PARTICIPANT SIGNATURE (age >18) Printed Name   Date 
(Or Legally Authorized Representative) 
 
_________________________________  _______________________  _________ 
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AUTHORIZATION TO USE or SHARE 
HEALTH INFORMATION1 THAT IDENTIFIES YOU FOR RESEARCH 
An Informed Consent Document for Research Participation may also be required. 
Form 2 must be used for research involving psychotherapy notes. 
 
Title of Research Project: An Evaluation of the Foot Tapping Test (FTT) in a Healthy Population  
Leader of Research Team: Rebecca D Larson, PhD 
Address: Department of Health and Exercise Science, 1401 Asp Avenue, Room 117 HHC, Norman 
OK 73019 
Phone Number:  405-325-6325 
If you decide to sign this document, University of Oklahoma Health Sciences Center (OUHSC) 
researchers may use or share information that identifies you (protected health information) for their 
research. Protected health information will be called PHI in this document. 
 
PHI To Be Used or Shared.  Federal law requires that researchers get your permission 
(authorization) to use or share your PHI. If you give permission, the researchers may use or share 
with the people identified in this Authorization any PHI related to this research from your medical 
records and from any test results.  Information used or shared may include all information relating to 
any tests, procedures, surveys, or interviews as outlined in the consent form; medical records and 
charts; name, address, telephone number, date of birth, race, government-issued identification 
numbers, and can include physical findings from questionnaires, dual X-ray absorptiometry (DXA) 
scan, and foot tapping test (FTT) data.  
Purposes for Using or Sharing PHI. If you give permission, the researchers may use your PHI to 
determine the reliability of the foot tapping test (FTT) and establish normative foot tapping rates for 
healthy individuals.  
Other Use and Sharing of PHI. If you give permission, the researchers may also use your PHI to 
develop new procedures or commercial products. They may share your PHI with other researchers, 
the research sponsor and its agents, the OUHSC Institutional Review Board, auditors and inspectors 
who check the research, and government agencies such as the Food and Drug Administration (FDA) 
and the Department of Health and Human Services (HHS), and when required by law.  The 
researchers may also share your PHI with no one outside the research team 
Confidentiality. Although the researchers may report their findings in scientific journals or meetings, 
they will not identify you in their reports. The researchers will try to keep your information 
                                                 
1
 Protected Health Information includes all identifiable information relating to any aspect of an individual’s 
health whether past, present or future, created or maintained by a Covered Entity. 
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confidential, but confidentiality is not guaranteed.  The law does not require everyone receiving the 
information covered by this document to keep it confidential, so they could release it to others, and 
federal law may no longer protect it. 
YOU UNDERSTAND THAT YOUR PROTECTED HEALTH INFORMATION MAY 
INCLUDE INFORMATION REGARDING A COMMUNICABLE OR NONCOMMUNICABLE 
DISEASE. 
Voluntary Choice. The choice to give OUHSC researchers permission to use or share your PHI for 
their research is voluntary.  It is completely up to you.  No one can force you to give permission.  
However, you must give permission for OUHSC researchers to use or share your PHI if you want to 
participate in the research and, if you cancel your authorization, you can no longer participate in this 
study. 
Refusing to give permission will not affect your ability to get routine treatment or health care unrelated 
to this study from OUHSC.   
Canceling Permission. If you give the OUHSC researchers permission to use or share your PHI, 
you have a right to cancel your permission whenever you want. However, canceling your permission 
will not apply to information that the researchers have already used, relied on, or shared or to 
information necessary to maintain the reliability or integrity of this research. 
End of Permission. Unless you cancel it, permission for OUHSC researchers to use or share your 
PHI for their research will never end.  
Contacting OUHSC: You may find out if your PHI has been shared, get a copy of your PHI, or 
cancel your permission at any time by writing to: 
Privacy Official                     or Privacy Board 
University of Oklahoma Health Sciences Center University of Oklahoma Health Sciences Center 
PO Box 26901     PO Box 26901 
Oklahoma City, OK 73190    Oklahoma City, OK 73190 
 
If you have questions, call: (405) 271-2511         or   (405) 271-2045. 
 
Access to Information. You have the right to access the medical information that has been collected 
about you as a part of this research study.  However, you may not have access to this medical 
information until the entire research study is completely finished.  You consent to this temporary 
restriction.  
Giving Permission.  By signing this form, you give OUHSC and OUHSC’s researchers led by the 
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Patient/Participant Name (Print): _________________________  
 
 
__________________________________________   _______________ 
Signature of Patient-Participant     Date 




__________________________________________   _______________ 
Signature of Legal Representative**     Date 
 
**If signed by a Legal Representative of the Patient-Participant, provide a description of the 
relationship to the Patient-Participant and the authority to act as Legal Representative: 
 
_______________________________________________________________________  
OUHSC may ask you to produce evidence of your relationship. 
 
A signed copy of this form must be given to the Patient-Participant or the Legal Representative at 
the time this signed form is provided to the researcher or his representative. 
 
                                      
IRB NUMBER: 7475
IRB APPROVAL DATE: 01/18/2017










Form 3.2 Health Status Questionnaire 
 
This questionnaire identifies adults for whom physical activity might be inappropriate 
or adults who should seek physician consultation before beginning a regular physical 
activity program. 
 
Section 1 Personal and Emergency Contact Information 
Name:    Date of birth:    
 
Address:    Phone:     
 
Physician’s name:      Height:    
 
Weight:     
 
Person to contact in case of emergency 
 
Name:    Phone:     
 
Section 2 General Medical History 
Please check the following conditions you have experienced. 
 
Heart History 
   Heart attack 
   Heart surgery 
 
   Cardiac rhythm disturbance 
   Heart valve disease 
   Cardiac catheterization  Heart failure 
   Coronary angioplasty (PTCA)  Heart transplantation 
   Cardiac pacemaker 
Symptoms 
   Congenital heart disease 
  You experience chest discomfort with exertion. 
  You experience unreasonable shortness of breath at any time. 
  You experience dizziness, fainting, or blackouts. 
  You take heart medications. 
Additional Health Issues 
  You have asthma or other lung disease (e.g., emphysema). 
  You have burning or cramping sensations in your lower legs with minimal 
physical activity. 
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  You have joint problems (e.g., arthritis) that limit your physical activity. 
  You have concerns about the safety of exercise. 
  You take prescription medications. 
  You are pregnant. 
 
Section 3 Risk Factor Assessment 
Risk Factors for Coronary Heart Disease 
  You are a man older than 45 yr. 
  You are a woman older than 55 yr, have had a hysterectomy, or are 
postmenopausal. 
  You have diabetes (type 1 or type 2). 
  You smoke or you quit smoking within the previous 6 mo. 
  Your blood pressure is >140/90 mmHg. 
  Your blood cholesterol is >200 mg · dl–1. 
  You have a close male blood relative (father or brother) who had a heart attack 
or heart surgery before the age of 55 or a close female blood relative (mother or 
sister) who had a heart attack or heart surgery before the age of 65. 
  You are physically inactive (you get <30 min of physical activity at least 3 days 
per wk). 
  Your waist circumference is >40 in. (101.6 cm in men) or >35 in. (88.9 cm in 
women). 
 
Section 4 Medications 
Are you currently taking any medication? Yes No 
 
If yes, please list all of your prescribed medications and how often you take them, 
whether daily (D) or as needed (PRN).     
 
 




Section 5 Physical Activity Patterns and Objectives 
List the type, frequency, intensity (e.g., low, moderate, strenuous), and duration of your 
weekly exercise.    
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List your specific goals for your exercise program.      
 
 
Please inform the fitness professional immediately of any changes that occur in your 
health status. 
 
Patient Information Release Form 
If you have answered yes to questions indicating that you have significant cardiac, 
pulmonary, metabolic, or orthopedic problems that may be exacerbated with exercise, 
you agree it is permissible for us to contact your physician regarding your health status. 
 
Signature:    Date:      
 
Fitness staff signature:     Date:      
 
To be completed by fitness professional (circle one): 
AHA/ACSM risk stratification:  Low Moderate High Physician consent: Yes No 
From E.T. Howley and B.D. Franks with G. Moore, 2007, Fitness Professional’s Handbook Instructor Guide, Fifth Edition. (Champaign, IL: Human Kinetics.) 
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Medical History Questionnaire 
 
Name: _____________________________________                   Date of Birth: _____________________ 
Address: __________________________________                    Phone Number: __________________ 
____________________________________________   alt #: _____________________ 
Email: ____________________________________ 
Age: ___________ 
Dominant side:   Left      Right     (circle) 
Blood Pressure: _______/________ 
Height: ___________   Weight: _____________   Shoe Size: _______________ 
Sex:    Male      Female   (circle)                    Gender:    Male    Female   (circle) 
Ethnicity:      Caucasian     African American     Hispanic    Asian    Other: ____________ 
Emergency contact name and number: _________________________________________________ 
 
Please answer the following questions: 
1. Have you ever been diagnosed with diabetes? 
Y      N     If “yes,” when where you diagnosed? __________________________ 
2. Have you ever been told by a physician that you have 
Osteoporosis/Osteopenia? 
Y      N 
3. Have you ever had a heart attack or stroke? 
Y      N    If “yes,”  what and when? __________________________________________ 
4. Have you ever been diagnosed with any disease affecting the brain, spine, or 
nerves? (ex: Multiple sclerosis, brain tumors, epilepsy, Parkinson’s disease, 
Neuropathy, ALS, etc.) 
Y     N   If “yes,” what and when? ___________________________________________ 
________________________________________________________________________________ 
5. Have you ever been diagnosed with arthritis? 
Y     N   If “yes,” when? 
6. Have you had any injuries of the lower limbs specifically involving bone, 
tendon, or ligament damage? 
Y     N   If “yes,” what and when? __________________________________________ 
_______________________________________________________________________________ 
7. Have you had any injuries of the lower limbs specifically involving the 
muscles? 
Y     N If “yes” what and when? ____________________________________________ 
_______________________________________________________________________________ 
8. Do you experience frequent pain in your lower limbs? 
Y    N  If “yes,” where and how often?______________________________________ 
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9. Do you have a decreased range of motion or mobility in your hips, knees, or 
ankles? 
Y    N  If “yes,” how much and where? _____________________________________ 
10.  Do you use an assistive device for walking? 
Y    N  If “yes,” what? ______________________________ 
11.  Do you experience any difficulties producing and maintaining rapid and 
repetitive movements? 
Y    N   If “yes,” then describe. _______________________________________________ 
12. Are you currently on any kind of medications? 
Y    N  If “yes,” what medication, amount taken, time on medication, 
and reason.   
________________________________________________________________________________
________________________________________________________________________________ 






I certify that these answers are accurate and complete 
 
 
Your Signature:                                                                                            Date:       
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 SHORT LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ.  Revised August 2002. 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
(August 2002) 
 
SHORT LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. 
Long (5 activity domains asked independently) and short (4 generic items) versions for use by 
either telephone or self-administered methods are available. The purpose of the questionnaires 
is to provide common instruments that can be used to obtain internationally comparable data on 
health–related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in Geneva in 
1998 and was followed by extensive reliability and validity testing undertaken across 12 
countries (14 sites) during 2000.  The final results suggest that these measures have 
acceptable measurement properties for use in many settings and in different languages, and are 
suitable for national population-based prevalence studies of participation in physical activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It is 
recommended that no changes be made to the order or wording of the questions as this will 
affect the psychometric properties of the instruments.  
 
Translation from English and Cultural Adaptation 
Translation from English is supported to facilitate worldwide use of IPAQ. Information on the 
availability of IPAQ in different languages can be obtained at  www.ipaq.ki.se. If a new 
translation is undertaken we highly recommend using the prescribed back translation methods 
available on the IPAQ website. If possible please consider making your translated version of 
IPAQ available to others by contributing it to the IPAQ website. Further details on translation 
and cultural adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical Activity 
Prevalence Study is in progress. For further information see the IPAQ website.  
 
More Information 
More detailed information on the IPAQ process and the research methods used in the 
development of IPAQ instruments is available at www.ipaq.ki.se and Booth, M.L. (2000).  
Assessment of Physical Activity: An International Perspective.  Research Quarterly for Exercise 
and Sport, 71 (2): s114-20.  Other scientific publications and presentations on the use of IPAQ 
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 SHORT LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ.  Revised August 2002. 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives.  The questions will ask you about the time you spent being 
physically active in the last 7 days.  Please answer each question even if you do not 
consider yourself to be an active person.  Please think about the activities you do at 
work, as part of your house and yard work, to get from place to place, and in your spare 
time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe 
much harder than normal.  Think only about those physical activities that you did for at 
least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical activities on one 
of those days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate 
activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal.  Think only about those physical activities that you did 
for at least 10 minutes at a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles tennis?  
Do not include walking. 
 
_____ days per week 
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 SHORT LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ.  Revised August 2002. 
4. How much time did you usually spend doing moderate physical activities on one 
of those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you have done 
solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the last 7 
days.  Include time spent at work, at home, while doing course work and during leisure 
time.  This may include time spent sitting at a desk, visiting friends, reading, or sitting or 
lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
This is the end of the questionnaire, thank you for participating. 
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